Acute Lymphoid Leukemia
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) HC (1) | CD19 + | Acute Lymphoid Leukemia | Blinatumomab | |
| FDA (1) | CD19 +, not BCR::ABL1 | Acute Lymphoid Leukemia | Blinatumomab | |
| FDA (2) HC (1) | BCR::ABL1 | Acute Lymphoid Leukemia | Dasatinib | |
| FDA (2) | CD33 + | Acute Lymphoid Leukemia | Gemtuzumab ozogamicin | |
| FDA (2) HC (2) | BCR::ABL1 | Acute Lymphoid Leukemia | Imatinib | |
| FDA (1) HC (1) | CD22 + | Acute Lymphoid Leukemia | Inotuzumab ozogamicin | |
| FDA (1) | BCR::ABL1 | Acute Lymphoid Leukemia | Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine | |
| FDA (1) HC (1) | ABL1 p.T315I, BCR::ABL1 | Acute Lymphoid Leukemia | Ponatinib | |
| FDA (1) | t(KMT2A;v) | Acute Lymphoid Leukemia | Revumenib | |
| FDA (1) | NPM1 p.W288Cfs*12 | Acute Lymphoid Leukemia | Revumenib |